Search Results - "Buglioni, S."

KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma by Gallina, F.T., Marinelli, D., Melis, E., Forcella, D., Taje, R., Buglioni, S., Visca, P., Torchia, A., Cecere, F.L., Botticelli, A., Santini, D., Ciliberto, G., Cappuzzo, F., Facciolo, F.

“…•It is unclear whether the KRAS G12C has a prognostic role in early stage LUAD.•In the stage I IRE cohort we found an association between KRAS G12C and worse…”
Get full text

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma by Scalera, S., Ricciuti, B., Mazzotta, M., Calonaci, N., Alessi, J.V., Cipriani, L., Bon, G., Messina, B., Lamberti, G., Di Federico, A., Pecci, F., Milite, S., Krasniqi, E., Barba, M., Vici, P., Vecchione, A., De Nicola, F., Ciuffreda, L., Goeman, F., Fanciulli, M., Buglioni, S., Pescarmona, E., Sharma, B., Felt, K.D., Lindsay, J., Rodig, S.J., De Maria, R., Caravagna, G., Cappuzzo, F., Ciliberto, G., Awad, M.M., Maugeri-Saccà, M.

“…KEAP1 mutations have been associated with reduced survival in lung adenocarcinoma (LUAD) patients treated with immune checkpoint inhibitors (ICIs),…”
Get full text

Small molecules targeted to the microtubule–Hec1 interaction inhibit cancer cell growth through microtubule stabilization by Ferrara, M, Sessa, G, Fiore, M, Bernard, F, Asteriti, I A, Cundari, E, Colotti, G, Ferla, S, Desideri, M, Buglioni, S, Trisciuoglio, D, Del Bufalo, D, Brancale, A, Degrassi, F

“…Highly expressed in cancer protein 1 (Hec1) is a subunit of the kinetochore (KT)-associated Ndc80 complex, which ensures proper segregation of sister…”
Get full text

Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells by Di Martile, M, Desideri, M, De Luca, T, Buglioni, S, Del Bufalo, D, Trisciuoglio, D

Get full text

Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells by Tupone, M.G, Trisciuoglio, D, Desideri, M, Di Martile, M, Buglioni, S, Loria, R, Ferraresi, V, Baldini, N, Biagini, R, Del Bufalo, D

Get full text

P011 A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node of breast cancer by Buglioni, S, Terrenato, I, Casini, B, D'Alicandro, V, Di Filippo, F, Mottolese, M, Pescarmona, E

Get full text

Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2 by Buglioni, Simonetta, D'Agnano, Igea, Cosimelli, Maurizio, Vasselli, Stefania, D'Angelo, Carmen, Tedesco, Manfredo, Zupi, Gabriella, Mottolese, Marcella

“…About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio‐pathological markers, predictive…”
Get full text

0092 A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by “one step nucleic acid amplification (OSNA)” in comparison with intensive histological investigation by Buglioni, S, Del Chierico, F, Conti, S, Visca, P, Perri, P, Di Filippo, F, Perrone Donnorso, R, Marandino, F

Get full text

339 One Step Nucleic Acid Amplification (OSNA) assay for molecular detection of sentinel lymph node metastases in early breast cancer classified according to molecular subtypes: an observational prospective study by Buglioni, S, Casini, B, Marino, M, Perri, P, Terrenato, I, Di Filippo, F, Marandino, F

Get full text

p53 Nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy by BUGLIONI, Simonetta, D'AGNANO, Igea, VASSELLI, Stefania, PERRONE DONNORSO, Raffaele, D'ANGELO, Carmen, BRENNA, Alessia, BENEVOLO, Maria, COSIMELLI, Maurizio, ZUPI, Gabriella, MOTTOLESE, Marcella

“…To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and…”
Get full text

56P The prognostic role of KRAS mutations in patients with early-stage lung adenocarcinoma after robotic lobectomy and systematic lymphadenectomy by Gallina, F.T., Marinelli, D., Forcella, D., Tajè, R., Ceddia, S., Fusco, F., Melis, E., Buglioni, S., Visca, P., Cappuzzo, F., Facciolo, F.

Get full text

1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial by Cappuzzo, F., Delmonte, A., Landi, L., Andrikou, K., Dal Maso, A., Minuti, G., Lee, C., Wang, X., Papi, M., Metro, G., Attili, I., Piantedosi, F.V., Pilotto, S., Gori, S., Rossi, G., Buglioni, S., Giannarelli, D., Bonanno, L.

Get full text

2022P ALBA project: Prognostic impact of laterality in small cell lung cancer by Landi, L., Resuli, B., D'Incecco, A., Tufman, A., Cannita, K., Minuti, G., Kauffmann-Guerrero, D., Laudisi, A., Behr, J., Buglioni, S., Faggiano, A., G.R. quaglione, Bolt, T.A., Marcozzi, B., Bellino, S., Cecere, F.L., Ciliberto, G., Reinmuth, N., Cappuzzo, F., La Salvia, A.

Get full text

Abstract P4-01-19: Liquid biopsy and re-biopsy: Tracking mutational trajectories in HER2+ breast cancer patients undergoing T-DM1 treatment by Allegretti, M, Giordani, E, Casini, B, Romania, P, Gasparro, S, Russillo, M, Gallo, E, Buglioni, S, Pescarmona, E, Cognetti, F, Ciliberto, G, Giacomini, P, Fabi, A

“…Abstract Background: The antibody-drug conjugate Trastuzumab emtansine (T-DM1, Kadcyla®) is standard of care in HER2+ breast cancer patients on clinical…”
Get full text

518 - Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells by Di Martile, M., Desideri, M., De Luca, T., Buglioni, S., Del Bufalo, D., Trisciuoglio, D.

Get full text

Role of P53 and Bcl-2 in Advanced Rectal Carcinomas Treated with Adjuvant Therapy by Piperno, G., Cosimelli, M., Perrone Donnorso, R., Mancini, R., Buglioni, S., Novelli, F., Sperduti, I., Zerbini, V., Garufi, C., Mottolese, M.

“…Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2,…”
Get full text

517 - Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells by Tupone, M.G., Trisciuoglio, D., Desideri, M., Di Martile, M., Buglioni, S., Loria, R., Ferraresi, V., Baldini, N., Biagini, R., Del Bufalo, D.

Get full text

The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity by Morini, M, Mottolese, M, Ferrari, N, Ghiorzo, F, Buglioni, S, Mortarini, R, Noonan, D M, Natali, P G, Albini, A

“…The alpha 3 beta 1 integrin is elevated in several types of metastatic tumor and has been associated with increased migration and invasion. Our analysis of a…”
Get full text

The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp‐9) activity by Morini, Monica, Mottolese, Marcella, Ferrari, Nicoletta, Ghiorzo, Federica, Buglioni, Simonetta, Mortarini, Roberta, Noonan, Douglas M., Natali, Pier Giorgio, Albini, Adriana

“…The α3β1 integrin is elevated in several types of metastatic tumor and has been associated with increased migration and invasion. Our analysis of a series of…”
Get full text

P3-07-02: Prediction of Non-Sentinel Lymph Node Status in Breast Cancer Patients with a Micrometastatic Sentinel Lymph Node Determined by the One Step Nucleic Acid Amplification (OSNA) Assay by Di Filippo, F, Casini, B, Gallo, E, Terrenato, I, Botti, C, Mottolese, M, Pescarmona, E, Marandino, F, Buglioni, S

“…Abstract Background Axillary lymph node dissection (ALND) may not be necessary in women with breast cancer (BC) who have micrometastasis in a sentinel lymph…”
Get full text